BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 1389493)

  • 1. Phase II study of interferon alfa-2a and dacarbazine in advanced melanoma. Biological Response Modifiers in Melanoma (BREMIM) Italian Cooperative Group.
    Eur J Cancer; 1992; 28A(10):1719-20. PubMed ID: 1389493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma.
    Bajetta E; Di Leo A; Zampino MG; Sertoli MR; Comella G; Barduagni M; Giannotti B; Queirolo P; Tribbia G; Bernengo MG
    J Clin Oncol; 1994 Apr; 12(4):806-11. PubMed ID: 8151323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II study of combined administration of dacarbazine and carboplatin with home therapy of recombinant interleukin-2 and interferon-alpha 2a in patients with advanced malignant melanoma.
    Ron IG; Mordish Y; Eisenthal A; Skornick Y; Inbar MJ; Chaitchik S
    Cancer Immunol Immunother; 1994 Jun; 38(6):379-84. PubMed ID: 8205559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fotemustine and dacarbazine plus recombinant interferon alpha 2a in thetreatment of advanced melanoma.
    Comella P; Daponte A; Casaretti R; Ionna F; Fiore F; Presutti F; Frasci G; Caponigro F; Gravina A; Parziale AP; Mozzillo N; Comella G
    Eur J Cancer; 1997 Jul; 33(8):1326-9. PubMed ID: 9301463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Updated analysis of an outpatient chemoimmunotherapy regimen for treating metastatic melanoma.
    Thompson JA; Gold PJ; Markowitz DR; Byrd DR; Lindgren CG; Fefer A
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S29-34. PubMed ID: 9457390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment of metastatic melanoma with dacarbazine recombinant interferon alfa 2A combination: results of multicentric study].
    Avril MF; Beerblock K; Dreno B; Delaunay M; Bonerandi JJ; Guillaume JC; Souteyrand P; Kalis B; Chevrant-Breton J; Verret J
    Bull Cancer; 1990; 77(12):1183-91. PubMed ID: 2081278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cisplatin, dacarbazine, and fotemustine plus interferon alpha in patients with advanced malignant melanoma. A multicenter phase II study of the Italian Cooperative Oncology Group.
    Daponte A; Ascierto PA; Gravina A; Melucci MT; Palmieri G; Comella P; Cellerino R; DeLena M; Marini G; Comella G;
    Cancer; 2000 Dec; 89(12):2630-6. PubMed ID: 11135225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II study of metastatic melanoma treated with a combination of interferon alfa 2b, dacarbazine and nimustine.
    Gröhn P; Kumpulainen E; Nuortio L; Hakala T; Vuoristo MS; Korpela M; Heikkinen M; Salmi R; Jakobsson M; Numminen S
    Eur J Cancer; 1992; 28(2-3):441-3. PubMed ID: 1591060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Combination of dacarbazine, cisplatin and interferon alpha in the treatment of metastatic melanoma].
    Tessier MH; Mansat E; Legoux B; Litoux P; Dreno B
    Ann Dermatol Venereol; 1996; 123(9):538-42. PubMed ID: 9615103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of interferon alpha-2a and dacarbazine in advanced melanoma.
    Bajetta E; Negretti E; Giannotti B; Brogelli L; Brunetti I; Sertoli MR; Bernengo MG; Sofra MC; Maifredi G; Zumiani G
    Am J Clin Oncol; 1990 Oct; 13(5):405-9. PubMed ID: 2220660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant interferon alpha-2a in combination with dacarbazine in the treatment of metastatic malignant melanoma: analysis of long-term responding patients.
    Ron IG; Inbar MJ; Gutman M; Merimsky O; Chaitchik S
    Cancer Immunol Immunother; 1993 Jul; 37(1):61-6. PubMed ID: 8513453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon-alpha 2a does not improve response or survival when combined with dacarbazine in metastatic malignant melanoma: results of a multi-institutional Australian randomized trial.
    Thomson DB; Adena M; McLeod GR; Hersey P; Gill PG; Coates AS; Olver IN; Kefford RF; Lowenthal RM; Beadle GF
    Melanoma Res; 1993 Apr; 3(2):133-8. PubMed ID: 8518552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Large randomized study of thymosin alpha 1, interferon alfa, or both in combination with dacarbazine in patients with metastatic melanoma.
    Maio M; Mackiewicz A; Testori A; Trefzer U; Ferraresi V; Jassem J; Garbe C; Lesimple T; Guillot B; Gascon P; Gilde K; Camerini R; Cognetti F;
    J Clin Oncol; 2010 Apr; 28(10):1780-7. PubMed ID: 20194853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dacarbazine and interferon alpha for stage IV malignant melanoma.
    Tamm I; Grimme H; Bergen E; Simon JC; Schöpf E; Mertelsmann R; Lindemann A; Brennscheidt U
    Oncology; 1997; 54(4):270-4. PubMed ID: 9216849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II multicenter trial of maintenance biotherapy after induction concurrent Biochemotherapy for patients with metastatic melanoma.
    O'Day SJ; Atkins MB; Boasberg P; Wang HJ; Thompson JA; Anderson CM; Gonzalez R; Lutzky J; Amatruda T; Hersh EM; Weber JS
    J Clin Oncol; 2009 Dec; 27(36):6207-12. PubMed ID: 19917850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II study of "decrescendo" interleukin-2 plus interferon-alpha-2a in patients with progressive metastatic melanoma after chemotherapy.
    Eton O; Buzaid AC; Bedikian AY; Smith TM; Papadopoulos NE; Ellerhorst JA; Hibberts JL; Legha SS; Benjamin RS
    Cancer; 2000 Apr; 88(7):1703-9. PubMed ID: 10738230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose escalation of dacarbazine combined with interferon alpha-2a, G-CSF and ondansetron in patients with metastatic melanoma.
    Buter J; Sleijfer DT; Willemse PH; van der Graaf WT; de Vries EG; Schraffordt Koops H; Mulder NH
    Anticancer Res; 1994; 14(3B):1325-8. PubMed ID: 7520681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Durable complete responses in metastatic melanoma treated with interleukin-2 in combination with interferon alpha and chemotherapy.
    Legha SS
    Semin Oncol; 1997 Feb; 24(1 Suppl 4):S39-43. PubMed ID: 9122733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dacarbazine and interferon-alpha 2a in advanced malignant melanoma: high response rate and prolongation of response duration occur in different patient subpopulations.
    Betticher DC; Lee SM; Morris C; Clemons M; Thatcher N
    Melanoma Res; 1995 Aug; 5(4):277-82. PubMed ID: 7496165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved results with the addition of interferon alfa-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma.
    Falkson CI; Falkson G; Falkson HC
    J Clin Oncol; 1991 Aug; 9(8):1403-8. PubMed ID: 2072144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.